We’re still figuring out the side effects of GLP-1 weight

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-10-09T10:00:40.368Z • Permanent link

Regulatory agencies worldwide are still grappling with the aftermath of GLP-1 weight-loss drugs, a class of medications that has revolutionized the treatment of obesity. Eli Lilly's Trulicity and Novo Nordisk's Ozempic, two of the most popular GLP-1 agents, have been at the center of controversy since their approval in 2014. The pharmaceutical giants have been accused of aggressively marketing these drugs to healthcare providers, touting their benefits without adequately disclosing the potential risks. One notable example is the case of Dr. James B. Buse, a renowned cardiologist who has been a vocal advocate for the safe use of GLP-1 agents. In 2020, Buse wrote an open letter to the FDA, expressing concerns over the lack of transparency in the marketing practices of pharmaceutical companies.

In 2022, the FDA launched an investigation into the marketing practices of Eli Lilly and Novo Nordisk, following a series of whistleblower complaints. The agency received reports of pharmaceutical sales representatives pushing the benefits of GLP-1 agents to doctors, downplaying the risks, and even offering kickbacks to healthcare providers. The investigation is ongoing, but the consequences for the pharmaceutical industry are already being felt. In 2023, Eli Lilly agreed to pay $27 million to settle charges related to its marketing practices for Trulicity.

Researchers at the University of California, San Francisco, have also been studying the effects of GLP-1 agents on patient outcomes. A 2023 study published in the Journal of Clinical Endocrinology and Metabolism found that patients taking these medications experienced significant weight loss, but also higher rates of hypoglycemia and pancreatic cancer. The study's lead author, Dr. Jennifer A. Schioppa, emphasized the need for further research into the long-term effects of GLP-1 agents on patient health.

The implications of the GLP-1 controversy extend far beyond the pharmaceutical industry. The rise of these medications has led to a shift in the way healthcare providers approach obesity treatment, with many doctors now relying on GLP-1 agents as a first-line treatment. However, the lack of transparency in marketing practices has created a lack of trust between healthcare providers and pharmaceutical companies. This can have serious consequences for patients, who may be left without access to effective treatment options.

Several companies, including Novo Nordisk and Eli Lilly, have faced backlash from investors and patients over their handling of the GLP-1 controversy. In 2023, Novo Nordisk's stock price took a hit following a report by the whistleblower website, ProPublica, which exposed the company's marketing practices for Ozempic. Patients and advocacy groups have also called for greater transparency and regulation of the pharmaceutical industry, arguing that these practices are putting profits over people.

The GLP-1 controversy is part of a larger pattern of regulatory scrutiny in the pharmaceutical industry. In recent years, agencies such as the FDA and the European Medicines Agency have increased their focus on marketing practices and patient safety. This is driven in part by the growing recognition of the need for greater transparency and accountability in the industry. However, the GLP-1 controversy also highlights the challenges of regulating complex pharmaceutical products, particularly those with multiple indications and potential side effects.